Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

TD Cowen analyst Tyler Van Buren initiated coverage of Soleno Therapeutics (SLNO) with a Buy rating and $110 price target The firm says Vykat XR ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Soleno Therapeutics Inc. advanced stock charts by Barron's. View SLNO historical stock data and compare to other stocks, and exchanges.

Review quarterly and annual revenue, net income, and cash flow for Soleno Therapeutics Inc (SLNO:XNAS) stock through the last fiscal year.